Nicotine Withdrawal

In the paper

“α5 KO mice do not display physical symptoms associated with both spontaneous and mecamylamine-precipitated nicotine withdrawal (Salas et al. 2009) nor withdrawal-induced hyperalgesia (Jackson et al. 2008).”

What the sources say

• ?Not checked — no full text of the sourcecites Salas et al. 2009 source
• Disputed

  Jackson et al.’s Results (‘Role of the α5 nAChR Subunit in Precipitated Nicotine Withdrawal’) report significant withdrawal-induced hyperalgesia in α5 knockout mice, contrary to the part of the sentence cited to Jackson et al. The statement about spontaneous and mecamylamine-precipitated physical symptoms is cited to Salas et al. (2009), not to this source. (LLM, conf=0.95)

  Checked by a reasoning model — may be wrong.

  cites Jackson et al. 2008 sourceExperimental — accuracy not yet measured

In the paper

“The Diagnostic and Statistical Manual of Mental Disorders (DSM-5) reports 7 primary symptoms associated with nicotine withdrawal: irritability/anger/frustration, anxiety, depressed mood, difficulty concentrating, increased appetite, insomnia, and restlessness (American Psychiatric Association 2013).”

What the sources say

• ?Could not verify

  The indexed passages under “Symptoms and patterns” (11 September 2026; no page given) describe depressive episodes, not nicotine withdrawal. Searches for the seven listed symptoms and for tobacco-withdrawal diagnostic symptoms found no passage that verifies the DSM-5 list or its count. (LLM, conf=0.78)

  cites American Psychiatric Association 2013 sourceExperimental — accuracy not yet measured

In the paper

“Genetic factors may also account for 29–53 % of the variance in withdrawal symptoms and approximately 50 % of the variance in quitting success (Xian et al. 2003, 2005; Pergadia et al. 2006).”

What the sources say

• ?Not checked — no full text of the sourcecites Xian et al. 2003 source
• Supported

  The Four-class nicotine withdrawal section reports that genetics accounted for 31.0% of variance in the withdrawal phenotype, within the cited range, and 50.6% of variance in failed cessation. The paper measures failed cessation rather than 'quitting success,' but its estimate supports the sentence's approximate figure for quitting outcomes. (LLM, conf=0.88)

  cites Xian et al. 2005 source
• Partly supported

  The Abstract reports 29% and 53% heritability for depressed mood during withdrawal in women and men, respectively, but gives 26–43% for most other symptoms and 9% for decreased heart rate. The paper does not report that genetic factors explain approximately 50% of variance in quitting success; its Introduction discusses cessation failure without that estimate. Page numbers are unavailable in our copy. (LLM, conf=0.86)

  cites Pergadia et al. 2006 sourceExperimental — accuracy not yet measured

In the paper

“α2 KO mice exhibit more somatic symptoms of withdrawal in novel environments (Lotfipour et al. 2013), but display no somatic signs of withdrawal in habituated environments (i.e., the home cage) (Salas et al. 2009).”

What the sources say

• Supported

  The Results section reports enhanced somatic nicotine-withdrawal behaviors in Chrna2−/− mice versus wild-type controls in a novel environment. The Discussion likewise says the knockout mice showed more paw tremors, head shakes, backing, and curls there. The home-cage clause is separately attributed to Salas et al. (2009), so it is not part of the claim judged against this citation. (LLM, conf=0.94)

  cites Lotfipour et al. 2013 source
• ?Not checked — no full text of the sourcecites Salas et al. 2009 source

In the paper

“β4 KO mice exhibit no somatic signs of nicotine withdrawal or hyperalgesia following mecamylamine-induced withdrawal (Salas et al. 2004).”

What the sources say

• Partly supported

  The Results section reports fewer somatic signs in nicotine-treated β4 knockout mice after mecamylamine, not no signs. It also reports no hyperalgesia in β4 knockout mice, but the Animals section specifies that the hyperalgesia tests were performed after interruption of nicotine infusion, rather than after mecamylamine-precipitated withdrawal. Page numbers are not provided in the supplied copy. (LLM, conf=0.94)

  cites Salas et al. 2004 sourceExperimental — accuracy not yet measured

In the paper

“behaviors that are controlled, at least in part, by nigrostriatal and mesolimbic dopaminergic activity (Cui et al. 2003)”

What the sources say

• Supported

  The Introduction states that locomotor activity is regulated in part by nigrostriatal dopaminergic neurotransmission and prepulse inhibition of acoustic startle by mesolimbic dopaminergic transmission. This directly supports the attributed claim. (LLM, conf=0.95)

  cites Cui et al. 2003 source

In the paper

“β2 KO mice exhibit levels of somatic signs of withdrawal and abstinence-induced hyperalgesia comparable to those of WT mice (Salas et al. 2004).”

What the sources say

• Partly supported

  The Results section reports that β2 knockout mice had somatic withdrawal scores similar to nicotine-treated controls after mecamylamine injection. Its hyperalgesia results compare wild-type mice with β4 knockout mice, not β2 knockout mice, so the claimed comparison of abstinence-induced hyperalgesia is not supported (page not specified in our copy). (LLM, conf=0.88)

  cites Salas et al. 2004 sourceExperimental — accuracy not yet measured

In the paper

“α3β4* nAChRs are the most likely contributors to physical components of withdrawal given the high levels of expression of α3 and β4 mRNA in the MHb, and the fact that the α3β4-selective α-conotoxin AuIB blocks the emergence of somatic signs of withdrawal (Jackson et al. 2013).”

What the sources say

• Partly supported

  The Results (section 3.4; page unavailable) report that AuIB dose-dependently reduced somatic signs of nicotine withdrawal, and the Discussion (section 4; page unavailable) links α3β4* receptors to physical withdrawal and notes high α3 and β4 subunit expression in the MHb. The copy does not specify that this expression is mRNA expression, and it says α5 receptors also mediate somatic signs; it therefore does not establish α3β4* receptors as the most likely contributors relative to other receptors. (LLM, conf=0.84)

  cites Jackson et al. 2013 sourceExperimental — accuracy not yet measured

In the paper

“As reported for the α5 KO mice (Gangitano et al. 2009), β3 KO mice have altered hypothalamic pituitary adrenal axis responses (Booker et al. 2007).”

What the sources say

• Supported

  The Results section (page not supplied) reports lower basal plasma corticosterone in female α5 knockout mice and higher basal hypothalamic CRF in male α5 knockout mice. These findings support the α5 comparison attributed to Gangitano et al.; the β3 finding is attributed to a different source. (LLM, conf=0.92)

  cites Gangitano et al. 2009 source
• ?Not checked — no full text of the sourcecites Booker et al. 2007 source

In the paper

“Changes were also reported for locomotor activity and prepulse inhibition of acoustic startle”

What the sources say

• Supported

  The Behavioral analysis section reports that β3 knockout mice had significantly higher open-field activity and significantly less prepulse inhibition of acoustic startle than wild-type littermates. The Behavioral effects of β3 deletion section summarizes both changes. (LLM, conf=0.95)

  cites Cui et al. 2003 source

In the paper

“a non-nicotine pharmaceutical currently FDA approved for the treatment of smoking cessation, varenicline, acts as a partial agonist at α6β2* nAChRs (Grady et al. 2010; Bordia et al. 2012).”

What the sources say

• Supported

  The Discussion (page not available) explicitly reports that varenicline is a partial agonist at α6β2*-nAChRs and describes it as marketed for smoking cessation. The paper does not specifically state its FDA approval status, but directly supports the pharmacological claim for which it is cited. (LLM, conf=0.92)

  cites Grady et al. 2010 source
• Supported

  The Introduction identifies varenicline as an FDA-approved drug used to help people quit smoking and states that this study found it to be a partial agonist at α6β2* nAChRs in rat and monkey striatum. The Discussion likewise reports its lower efficacy than nicotine at these receptors in both species. (LLM, conf=0.94)

  cites Bordia et al. 2012 source

In the paper

“There was no influence on the somatic symptoms of withdrawal, suggesting a selective role for α6 nAChR subunits in the affective manifestations of withdrawal (Jackson et al. 2009).”

What the sources say

• Supported

  The Discussion reports that an α6-selective antagonist blocked anxiety-related behavior and conditioned place aversion during nicotine withdrawal, but had no effect on somatic signs. The authors identify this as a role for α6-containing receptors in affective, but not physical, withdrawal. (LLM, conf=0.94)

  cites Jackson et al. 2009 source

In the paper

“While the DAergic VTA has been widely implicated in the rewarding aspects of addictive drugs, it has also been shown to participate in the signaling of aversion and lack of expected reward (Schultz et al. 1998; Ungless et al. 2004; Tobler et al. 2007; De Biasi and Dani 2011).”

What the sources say

• ?Not checked — no full text of the sourcecites Schultz et al. 1998 source
• ?Not checked — no full text of the sourcecites Ungless et al. 2004 source
• Partly supported

  The Discussion (page unavailable) says dopamine-neuron responses are stronger for cues predicting greater reward, supporting a general role in reward signaling. It does not establish that the VTA signals aversion or the absence of an expected reward, or address the rewarding effects of addictive drugs. (LLM, conf=0.81)

  cites Tobler et al. 2007 sourceExperimental — accuracy not yet measured

In the paper

“It has been suggested that receptor desensitization may be a major contributor to the upregulation observed in chronic users of nicotine-containing products (Benowitz 2008).”

What the sources say

• Supported

  The Biology of Nicotine Reinforcement (p. 4) says that repeated nicotine exposure increases brain nicotinic receptors and that this upregulation is believed to occur in response to nicotine-mediated receptor desensitization. The claim preserves the paper’s tentative framing. (LLM, conf=0.90)

  cites Benowitz 2008 source

In the paper

“Furthermore, chronic nicotine treatment upregulated a variety of nAChRs in the hippocampus, and the duration of β2 subunit upregulation relative to other nAChR subunits most closely corresponded to the total duration of memory-associated withdrawal symptoms (Gould et al. 2012).”

What the sources say

• Partly supported

  Results §3.2 (page unavailable) reports increased hippocampal cytisine-sensitive binding, associated with α4β2* receptors, on a time course similar to the contextual-learning withdrawal deficit. It found no increase in hippocampal cytisine-resistant binding; Results §3.3 found no increase in β2 subunit mRNA. The paper therefore supports a relationship involving β2-containing receptors, not the claim that various hippocampal receptor types were upregulated or that β2 subunit upregulation was compared with other subunits. (LLM, conf=0.90)

  cites Gould et al. 2012 sourceExperimental — accuracy not yet measured

In the paper

“This effect was not attributable simply to a lowered threshold of fear responses inherent to the effects of nicotine because cued FC was equivalent between nicotine-treated and nicotine-naïve groups.”

What the sources say

• Supported

  The Results report impaired contextual fear conditioning during withdrawal but no differences among groups in cued fear conditioning (Figure 1; Results). The discussion accompanying Figure 2 says these findings suggest nicotine does not increase fear in general, supporting the claim that a general change in fear responses does not explain the contextual effect. (LLM, conf=0.92)

  cites Davis et al. 2005 source

In the paper

“Nicotine withdrawal leads to an increase in CRF in the CeA, and blockade of CRF1 receptors diminishes nicotine withdrawalinduced anxiety-like behavior (George et al. 2007).”

What the sources say

• Supported

  The Results report that mecamylamine-precipitated withdrawal increased CRF in the central nucleus of the amygdala in nicotine-dependent rats. They also report that a CRF1 receptor antagonist blocked the withdrawal-induced increase in defensive burying, a measure of anxiety-like behavior. (LLM, conf=0.94)

  cites George et al. 2007 source

In the paper

“The MHb also hosts the expression of norepinephrine (NE), serotonin, ATP, and several neuropeptides (Dao et al. 2014).”

What the sources say

• Supported

  The section “Neurokinins participate in the nicotine-induced enhancement of excitability in the MHb” explicitly lists norepinephrine, serotonin, ATP, and numerous neuropeptides as expressed in the MHb. The excerpt does not indicate a page number. (LLM, conf=0.95)

  cites Dao et al. 2014 source

In the paper

“The LHb sends excitatory glutamatergic projections to the RMTg and is a major component of the circuit underlying negative reward (Dani and De Biasi 2013).”

What the sources say

• Supported

  In “THE DOPAMINE SYSTEMS” (page not provided), the paper describes excitatory glutamatergic projections from the LHb to the RMTg. It also says this connection strongly influences dopamine activity and reward prediction, with LHb activity increasing when an expected reward is omitted—supporting its described role in negative reward processing. (LLM, conf=0.91)

  cites Dani and De Biasi 2013 source

In the paper

“Additionally, infusion of an α3β4* nAChR-selective antagonist into the IPN elicited somatic withdrawal signs in nicotine-naïve mice and an even greater number of total symptoms in mice chronically treated with nicotine (Zhao-Shea et al. 2013).”

What the sources say

• Supported

  The Results section on β4 nAChR blockade (page not available) reports that IPN infusion of SR16584 induced withdrawal-like symptoms in nicotine-naïve mice and more total symptoms in chronically nicotine-treated mice. The paper describes SR16584 as selective for β4-containing nAChRs and cites a study of α3β4-selective ligands. (LLM, conf=0.88)

  cites Zhao-Shea et al. 2013 source

In the paper

“Activity in the RMTg increases upon exposure to aversive stimuli and decreases upon exposure to reward stimuli, representing inversely correlated signaling patterns (Hong et al. 2011).”

What the sources say

• Partly supported

  The Results (‘Reward-related properties of primate RMTg neurons’; page not provided) report that reward-negative neurons increased activity when an expected reward was absent and decreased activity when an unexpected reward occurred. The paper also reports reward-positive neurons with the opposite pattern. It supports inverse responses to reward versus non-reward in a subset of RMTg neurons, but does not establish the claimed response to aversive stimuli generally. (LLM, conf=0.88)

  cites Hong et al. 2011 sourceExperimental — accuracy not yet measured

In the paper

“The habenular complex, comprising the lateral (LHb) and medial (MHb) nuclei, is a diencephalic, epithalamic structure located ventrally along the dorsal third ventricle (Dani and De Biasi 2013).”

What the sources say

• Partly supported

  The Dopamine Systems section says the lateral and medial habenula form the habenula complex, an epithalamic structure by the third ventricle. It does not specify that the complex lies ventrally along the dorsal third ventricle; that more precise location is unsupported by this passage. No page number is provided in our copy. (LLM, conf=0.86)

  cites Dani and De Biasi 2013 sourceExperimental — accuracy not yet measured

In the paper

“Currently, the literature suggests that multiple genetic loci influence the severity of withdrawal symptoms and the ability to abstain from smoking.”

In the paper

“Indeed, a transgenic mouse model that overexpresses β4 nAChR subunits exhibits altered nicotine consumption and CPA (Frahm et al. 2011)”

What the sources say

• ?Not checked — no full text of the sourcecites Frahm et al. 2011 source

In the paper

“The MHb/IPN pathway plays a crucial role in mediating the physical manifestations of nicotine withdrawal and is the likely location of the effects of α5-containing nAChR on this phenotype (Salas et al. 2009).”

What the sources say

• ?Not checked — no full text of the sourcecites Salas et al. 2009 source

In the paper

“Because AuIB does not interfere with the affective symptomatology of withdrawal in the EPM and CPA paradigms, α6β4* nAChRs might be involved.”

In the paper

“The withdrawal syndrome exhibited can be alleviated by nicotine administration—akin to nicotine replacement strategies such as nicotine patches or gum—or by administration of pharmacological agents used as cessation aids in humans, such as bupropion or varenicline (Rennard and Daughton 2014).”

What the sources say

• ?Not checked — no full text of the sourcecites Rennard and Daughton 2014 source

In the paper

“Overall, these results suggest participation of β2 nAChR subunits in the signaling responsible for affective, but not somatic, symptoms of nicotine withdrawal.”

In the paper

“Conversely, co-expression of β3 increases α6β2 and α6β4 receptor levels and enhances nicotine-induced upregulation of α6β2β3 receptors compared to α6β2 receptors (Tumkosit et al. 2006).”

What the sources say

• ?Not checked — no full text of the sourcecites Tumkosit et al. 2006 source

In the paper

“Thus far, several brain structures have been already implicated in the withdrawal syndrome.”

In the paper

“Different anatomical structures in the CNS express distinct populations of nAChRs.”

In the paper

“Accordingly, as the rates of desensitization and recovery from receptor upregulation during nicotine withdrawal are incongruent, a physiological landscape is established in which there are more receptors expressed than would be present in nicotine-naïve individuals, and these receptors are less responsive to agonist binding.”

In the paper

“The mesocorticolimbic dopamine (DA) system has been identified as critical to the development of addictive behaviors, and DA signaling is involved in reward-based reinforcement of drug-derived behaviors.”

In the paper

“Candidate SNPs can have a multitude of biochemical functions, such as altering DNA methylation, histone modification, or accessibility of DNA to transcription factor binding that can impact when, where, and how much a gene, and its protein, is expressed.”

In the paper

“The syndrome is most severe in the first week, but it can persist for longer periods of time.”

In the paper

“Increasing attention is being paid to the functional analysis of rare variants, as common variants can explain only a small percentage of the variance in smoking-related phenotypes.”

In the paper

“Mice chronically treated with nicotine exhibit symptoms of withdrawal upon microinjection of mecamylamine into the MHb and IPN, but fail to manifest withdrawal symptoms when mecamylamine is injected to the cortex, hippocampus, or VTA (Salas et al. 2009).”

What the sources say

• ?Not checked — no full text of the sourcecites Salas et al. 2009 source

In the paper

“The habenula has been demonstrated to participate in the signaling underlying fear, anxiety, depression, and stress (Viswanath et al. 2013).”

What the sources say

• ?Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

  cites Viswanath et al. 2013

In the paper

“The system has been implicated in stress-related components of drug withdrawal and is a site of interaction between corticotropinreleasing factor (CRF) and NE transmission.”

In the paper

“The IPN is located in the ventral midbrain, with the VTA and median raphe nucleus located dorsally.”

In the paper

“Given the polygenic nature of nicotine addiction, many other mechanisms and many other brain areas are likely to influence the manifestations of withdrawal.”

In the paper

“More work is necessary at the bench and in the clinic, as a collection of genes likely operates collectively to predispose or protect individuals to or from nicotine addiction and withdrawal.”

In the paper

“During this time, relapse is incentivized by the ability of nicotine to alleviate or abolish withdrawal symptoms.”

In the paper

“Genetic studies of nicotine dependence and smoking cessation have identified several risk factors using GWAS, candidate gene approaches, and pharmacogenetic analyses.”

In the paper

“For many of the SNPs, however, there is no change in protein sequence, and therefore, it is harder to formulate clear functional hypothesis.”

In the paper

“In addition, there are cognitive deficits that manifest during nicotine withdrawal, including difficulty concentrating, increased reaction times in tasks requiring sustained attention, and impaired episodic and working memory (Myers et al. 2008; Wesnes et al. 2013).”

What the sources say

• ?Not checked — no full text of the sourcecites Myers et al. 2008 source
• ?Not checked — no full text of the sourcecites Wesnes et al. 2013 source